Now Available — GMP-grade R-PSMA I&T (Zadavotide guraxetan)

GMP-grade R-PSMA I&T (Zadavotide guraxetan) is now available from Huayi 

As a high-purity, R-enantiomer PSMA ligand optimized for radiolabeling with ⁶⁸Ga for PET imaging and ¹⁷⁷Lu for targeted therapy, R-PSMA I&T offers exceptional stability, selectivity, and reproducibility for radiopharmaceutical applications.

Manufactured to meet European Pharmacopoeia standards for Lutetium (¹⁷⁷Lu) Zadavotide/Guraxetan injection, our GMP-grade product supports advanced theranostic research and precision oncology applications.

DMF submission to the U.S. FDA is planned for December 2025, and ASMF submission in Europe is scheduled for January 2026, further supporting global regulatory readiness and clinical accessibility.

Weineisen M. et al. 68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies. J Nucl Med, 2015, 56(8):1169-76.
WHO. International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed International Nonproprietary Names: List 132. WHO Drug Information, Vol. 38 , No. 4, 2024.